EUVIMEDEUVIMED entdecken
Open Access

Evaluation of Ischemia-Modified Albumin, Malondialdehyde, and Advanced Oxidative Protein Products as Markers of Vascular Injury in Diabetic Nephropathy

Afzal Ahmad, Poornima Manjrekar, Charu Yadav, Ashish Agarwal, Rukmini Mysore Srikantiah, Anupama Hegde

Biomarker Insights · 2016-01 · 11 · BMI.S39053

DOI: 10.4137/bmi.s39053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomarker Insights, online erschienen am 02.05.2016. Verfasst von Afzal Ahmad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Kasturba Medical College, Mangalore, Manipal University, Karnataka, India. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM This study aimed at evaluation of ischemia-modified albumin (IMA), malondialdehyde (MDA), and advanced oxidative protein products (AOPP) as markers of vascular injury in diabetic nephropathy (DN) with derivation of cutoff values for the same. Materials and Methods Study population comprised 60 diabetes patients and 30 controls, with diabetes patients further categorized into three groups based on urine albumin/creatinine ratio (UACR) of 300 mg/g of creatinine (overt DN). Serum IMA, MDA, and AOPP were estimated by enzyme-linked immunosorbent assay; HbA1c, serum creatinine, urine albumin, and urine creatinine were estimated using automated analyzers. Statistical analysis was done using analysis of variance, Pearson's correlation coefficient, and receiver-operating characteristic curve.

Results

A statistically significant difference was found in the levels of IMA among patients with early DN (154 ng/mL), diabetes without nephropathy (109.4 ng/mL), and healthy controls (45.7 ng/mL), with highest levels in early DN cases. Similar increase was seen in AOPP as well. A significant correlation was observed between IMA and UACR in diabetes without nephropathy ( r = 0.448).

Conclusion

The present study postulates serum IMA as a novel biomarker for the assessment of disease progression in diabetes even before microalbuminuria, and a cutoff point ≥99 ng/mL can be used for detection of early DN.

Schlagwörter

Stichwörter der Autor:innen

advanced oxidative protein productsdiabetic nephropathyischemia-modified albuminmalondialdehydevascular injury

Autor:innen und Institutionen

  • Department of Biochemistry, Kasturba Medical College, Mangalore, Manipal University, Karnataka, India.

Zitieren

APA

Ahmad, A., Manjrekar, P., Yadav, C., Agarwal, A., Srikantiah, R. M., & Hegde, A. (2016). Evaluation of Ischemia-Modified Albumin, Malondialdehyde, and Advanced Oxidative Protein Products as Markers of Vascular Injury in Diabetic Nephropathy. Biomarker Insights, 11, BMI.S39053. https://doi.org/10.4137/bmi.s39053

Vancouver

Ahmad A, Manjrekar P, Yadav C, Agarwal A, Srikantiah RM, Hegde A. Evaluation of Ischemia-Modified Albumin, Malondialdehyde, and Advanced Oxidative Protein Products as Markers of Vascular Injury in Diabetic Nephropathy. Biomarker Insights. 2016;11:BMI.S39053. doi:10.4137/bmi.s39053

BibTeX
@article{Ahmad2016,
  author = {Ahmad, Afzal and Manjrekar, Poornima and Yadav, Charu and Agarwal, Ashish and Srikantiah, Rukmini Mysore and Hegde, Anupama},
  title = {Evaluation of Ischemia-Modified Albumin, Malondialdehyde, and Advanced Oxidative Protein Products as Markers of Vascular Injury in Diabetic Nephropathy},
  journal = {Biomarker Insights},
  year = {2016},
  volume = {11},
  pages = {BMI.S39053},
  doi = {10.4137/bmi.s39053}
}
Kostenlos starten →